Phase 2 N=16 Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
B-Cell Acute Lymphoblastic Leukemia, Adult
Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Phase 2 N=42 Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Primary: Overall Complete Remission Rate at Day 28 After CART-19 Therapy — 8; 10; 6; 6 Participants
Phase 2 N=64 Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Diffuse Large B-Cell Lymphoma
Primary: Overall Response (OR) Rate — 36 Participants
Phase 3 N=41 Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
B-Cell Non Hodgkin Lymphoma
Primary: Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR) — 22.0 Percentage of participants
Phase 2 N=45 Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…
Phase 1 N=26 Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell
Lymphoma, Non-Hodgkin · Lymphoma, B-Cell · Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events After CAR 20/19-T Cell Infusion — 7; 4; 22 Serious Adverse Events
Phase 1 N=17 Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
Acute Lymphoblastic Leukemia
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0 Participants
Phase 3 N=322 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694
Phase 2 N=106 Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
Acute Lymphoblastic Leukemia
Primary: Number of Subjects With Event-Free Survival in Patients With Newly Diagnosed VHR B-ALL or High-risk Relapse of B-ALL 1 Year After Treatment. — 68.9 percentage of subjects
Phase 2 N=18 HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
Refractory B-Lineage Leukemia · Relapsed B-Lineage Leukemia · Refractory B-Lineage Lymphoma
Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events
Phase 2 N=60 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
Phase 2 N=74 Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)
Lymphoma, Non-Hodgkin · Lymphoma, Nonhodgkin · Lymphoma, B-Cell
Primary: Overall Response Rate (ORR) — 80.3 Percent of Participants — p=<.0001
Phase 2 N=47 Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
High-risk Diffuse Large B-Cell Lymphoma
Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants
Phase 4 N=44 A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Complete Remission (CR) or Complete Remission With Incomplete Hematological Recovery (CRi) as Per Investigator's Assessment According to…
Phase 2 N=34 Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants
Phase 1 N=51 Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
B-ALL · B-cell Non Hodgkin Lymphoma · DLBCL
Primary: Rate of Successful Manufacture of CD22 CAR T Cells — 94; 100; 100 Percentage
Phase 2 N=18 Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
B-cell Adult Acute Lymphoblastic Leukemia (ALL) · Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) · Recurrent Adult Acute Lymphoblastic Leukemia (ALL)
Primary: Response Rate (RR) — 11 Participants
Phase 1 N=21 Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Primary: Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. — 3; 2 Participants
Phase 2 N=15 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
Phase 2 N=35 Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate (ORR) at the End of the Induction Phase — 17.1 percentage of participants
Phase 2 N=35 Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults
Acute Lymphoblastic Leukemia
Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants
Phase 1 N=26 CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
Hematopoietic/Lymphoid Cancer · Adult Acute Lymphoblastic Leukemia in Remission · B-cell Adult Acute Lymphoblastic Leukemia
Primary: Number of Participants With Adverse Events — 20 participants
Phase 2 N=30 Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients
Phase 2 N=45 MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
Diffuse Large B-Cell Lymphoma · Transformed Follicular Lymphoma · Mantle Cell Lymphoma
Primary: Number of Participants With Clinically Significant Vital Signs Findings (Treatment Related and Unrelated) [Phase 1] — 0; 0; 3; 1 participants
Phase 2 N=189 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 42.9…
Phase 3 N=184 A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
Lymphoma, Non-Hodgkin
Primary: Event-free Survival (EFS) Per Independent Review Committee (IRC) — 2.4; 29.5 Months
Phase 2 N=25 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-cell Lymphoma
Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants
Phase 2 N=81 Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
Lymphoma, Large-Cell, Diffuse
Primary: Number of Participants With Objective Response — 9 participants
Phase 2 N=65 Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044